Plateau concentrations were maintained over a period of nearly 2 to 3 weeks, showing dose proportional peak concentrations of about 0.07 ng/mL/mg.
Evidence role
Reported: reviewed reported observation that should not be pooled as a comparable value yet
Assay / model
human
Condition
Octreotide · d0b7fe9e-7000-4b79-ba3b-291ce92c14f9 · 12.3 Pharmacokinetics · cmax dose proportional peak text · Plateau concentrations were maintained over a period of nearly 2 to...
